Lyme Disease ELISpot Human IFN-γ Kit

Product Details

Application

The Lyme Disease Human IFN-γ Enzyme-Linked ImmunoSpot (ELISpot) kit is a highly sensitive method used to detect and quantify individual cells that secrete IFN-γ after stimulation with the ImmuneSelect Lyme Disease Peptide Pool. This assay is utilized to monitor cellular immune responses at the single-cell level and reliably detects and measures human IFN-γ secretion by Lyme Disease stimulated effector cells.

Description

Lyme disease, caused by the bacterium *Borrelia burgdorferi*, is the most common vector-borne illness in North America and Europe. Transmitted by the bite of infected ticks, Lyme disease can lead to a wide range of clinical manifestations, including erythema migrans (a characteristic skin rash), arthritis, carditis, and neurological symptoms such as meningitis and facial palsy. Early diagnosis is critical to prevent the progression to more severe, disseminated forms of the disease, which can result in long-term health complications, increased healthcare costs, and significant morbidity. Diagnosis and prompt antibiotic treatment initiated in the early stages of Lyme disease typically leads to a full recovery, whereas delayed diagnosis and treatment are associated with chronic symptoms and more complex management.

Product Specifications

Product	ViraxImmune Lyme Disease ELISpot Human IFN-γ kit
Application	ELISpot
Analyte	IFN-γ
Reactivity	Human
Specificity	Human IFN-γ.
Storage	Store plates and reagents between 2 and 8°C. Peptide pool vial must be stored at -20 °C or below.
Shelf life	18 months from date of receipt.

Kit content

Peptide pools	ImmuneSelect Lyme Disease (41 peptides from Borreliella burgdorferi)
Plate	ELISpot plate precoated with IFN-γ capture antibody
Detection mAb	Biotinylated recombinant IFN-γ antibody
Enzyme conjugate	Streptavidin-ALP (Alkaline Phosphatase)

Substrate	BCIP/NBT Ready-to-use solution
Blocking agent	Bovine Serum Albumin (BSA)